Indian Dr. Reddy's in Talks to Buy Haleon's Nicotinell, Sky News Reports
Provided by
Dow Jones
--Indian pharmaceutical group Dr. Reddy's Laboratories is in ongoing talks to buy the anti-smoking aid Nicotinell from Haleon, Sky News reports, citing unnamed sources.
--Financial details regarding how much Dr Reddy's might pay to Haleon--which was spun out of GSK and Pfizer's consumer-healthcare business--remain unclear, but it is unlikely to be as much as the $800 million suggested in a previous report, Sky News reports.
--The companies weren't immediately available for comment.
Full story: https://bit.ly/3HFrAOx
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
January 16, 2024 08:43 ET (13:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel in Earnings Season
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth